T1294 Severe Immunosuppressant Induced Ileal Crohn's Disease-Like Injury in Solid Organ Transplantation Recipients Treated with Mycophenolate Mofetil (MMF)

application of anandamide 5mg/kg. Control group received TNBS only (n=6) (vehicle control group received only 50% ethanol solution 150 μl (n=6)). On day 3 the animals were sacrificed and their colon excised. A scoring system was used to describe clinical and macroscopic changes. Furthermore, histological evaluation and measurement of COX2 and TNFalpha as inflammatory markers was performed by Western blot and qPCR. Results: Intraperitoneal anandamide (5 mg/kg/die) significantly attenuated TNBS-induced experimental colitis, quantified by the major colitis score. TNBS-control group showed higher stool score (3.5±0.38, n=6) and decreased body weight than AKR mice treated with anandamide. In addition, anandamide treatment decreased colon weight gain and increased colon length respectively in comparison to vehicle treated mice. TNBS treated AKR mice demonstrated profound colon weight gain (187.85%±1.36%, n=6) compared to vehicle group, whereas anandamide treatment reduced colon weight gain compared to control group (28.9%±8.2, n=6). Furthermore, in TNBS treated AKR mice colon length was reduced (23.53%±1.72, n=6) compared to vehicle group, whereas anandamide treatment attenuated colon length reduction compared to TNBS-control group. Quantitatively, the histologic score was reduced in the anandamide group, additionally COX2 and TNF alpha levels were reduced in anandamide treated mice compared to AKR mice with TNBS-induced colitis. Conclusion: These results suggest that systemically administered anandamide attenuates experimental colitis in mice, and that orally active cannabinoids might have therapeutic potential for the treatment of IBD.